Quantcast

FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),today announced that the U.S. Food and Drug Administration (FDA)approved Tecentriq® (atezolizumab), in combinationwith carboplatin and etoposide (chemotherapy), for the initial(first-line) treatment of adults with extensive-stage small cell lungcancer (ES-SCLC).

Read more

Quicker pathway to a pivotal trial for larger patient population than planned for Actinium’s CD33

@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM

Read more